Schizophrenia is a persistent and severe psychiatric disorder characterized by disruptions in cognition, perception, emotion, and behavior. Key symptoms include hallucinations, delusions, disorganized thinking, and impaired cognitive function. Typically emerging during late adolescence or early adulthood, the condition stems from a multifactorial etiology involving genetic, neurological, and environmental components. Affecting nearly 1% of the global population, schizophrenia imposes a substantial burden on personal, social, and occupational functioning.

Although a cure remains elusive, schizophrenia is manageable through a combination of antipsychotic medications, behavioral therapy, and psychosocial support. Early intervention plays a critical role in improving long-term outcomes. However, issues like medication non-compliance and adverse side effects such as weight gain and sedation remain significant challenges in ongoing care.

Schizophrenia Epidemiology – 7MM (2020–2034)

Key segmentation areas include:

• Total Prevalent Cases

• Diagnosed Prevalent Cases

• Gender-Based Distribution

• Severity-Based Diagnosed Cases

• Age-Specific Treated Population

• Overall Treated Population

2022 Epidemiological Highlights

• Approximately 6 million prevalent cases were reported across the 7MM.

• The United States accounted for the largest share with ~2.7 million cases (45.05%).

• The EU4 and the UK recorded about 2.2 million cases (37.36%), with Germany leading this group (28.5%).

• Japan represented nearly 1 million cases (17.59%).

In the US:

• Around 1.4 million patients had a formal diagnosis (37.2% of total cases).

• Gender distribution showed a slightly higher prevalence in males (53.63%) versus females (46.37%).

• Severity split among diagnosed individuals:

  • Mild: ~567K (40.2%)

  • Moderate: 37.03%

  • Severe: 22.81%

Schizophrenia Market Overview

In 2022, the schizophrenia market across the 7MM reached an estimated value of USD 5.7 billion.

Market Drivers

• Progress in research and development, particularly with novel antipsychotic therapies offering better efficacy and safety.

• Enhanced awareness, diagnostic accuracy, and screening practices are boosting early detection and increasing the number of patients receiving treatment.

Market Barriers

• High treatment costs, especially for long-acting injectables and newer therapies, continue to limit access in lower-resource regions.

• Side effects such as sedation and metabolic issues often lead to poor treatment adherence and impact patient outcomes.

Emerging Therapies to Watch

The schizophrenia treatment landscape is rapidly evolving with a robust pipeline of innovative drug candidates, including:

• Iclepertin (BI-425809)

• Ulotaront (SEP-363856)

• Brilaroxazine (RP-5063)

• Roluperidone (MIN-101/MT-210)

• NUPLAZID (pimavanserin)

• OKEDI/RISVAN (risperidone ISM)

• Olanzapine LAI (TEV-44749/mdc-TJK)

• LYN-005 (oral risperidone, long-acting)

• Valbenazine (NBI-98854)

• LY03010 (ER paliperidone palmitate)

• Evenamide (NW-3509)

• And more in development

Explore the latest insights and emerging therapies in DelveInsight’s detailed Schizophrenia Market Report.

Leading Industry Players

Several pharmaceutical companies are actively shaping the schizophrenia market landscape:

• Boehringer Ingelheim

• Sumitomo Pharma

• Otsuka Pharmaceuticals

• Reviva Pharmaceuticals

• Minerva Neurosciences

• Mitsubishi Tanabe Pharma

• Karuna Therapeutics

• Bristol Myers Squibb

• Acadia Pharmaceuticals

• Rovi Pharmaceuticals

• Teva Pharmaceutical

• MedinCell

• Lyndra Therapeutics

• Neurocrine Biosciences

• Luye Pharma

• Royalty Pharma

• And others

Gain visual insights and stats from this Schizophrenia Market Infographic by DelveInsight.